Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Bone formation in senile osteoporosisbone formation in senile osteoporosis

ABSTRACT: Bone formation in senile osteoporosisbone formation in senile osteoporosis

PROVIDER: PRJNA865868 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR20339871.fastq.gz	Fastqsanger.gz
	SRR20339872.fastq.gz	Fastqsanger.gz
	SRR20339873.fastq.gz	Fastqsanger.gz
	SRR20339874.fastq.gz	Fastqsanger.gz
	SRR20339875.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 21

Similar Datasets

BMAL1-TTK-H2Bub1 loop deficiency contributes to impaired BM-MSC-mediated bone formation in senile osteoporosis

Project description:BMAL1-TTK-H2Bub1 loop deficiency contributes to impaired BM-MSC-mediated bone formation in senile osteoporosis

| PRJNA865870 | ENA

Bone formation in senile osteoporosisbone formation in senile osteoporosis

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-08-03 | GSE210426 | GEO

Transcriptome Alteration Between Young and Senile Human Bone MSC

Project description:In order to uncover mechanisms of hBMSC senescence, we performed high-throughput RNA-seq using young and senile human bone MSC (hBMSC).

2023-09-20 | GSE160273 | GEO

Transcriptome Alteration Between Young and Senile Human Bone MSC

Project description:Transcriptome Alteration Between Young and Senile Human Bone MSC

| PRJNA672852 | ENA

Adipocyte-Specific TMEM41B Deficiency Enhances Bone Formation and Attenuates Osteoporosis via the YY1-Calreticulin Axis

Project description:Osteoporosis (OP) is a prevalent skeletal disorder characterized by excessive bone marrow adiposity and impaired osteogenesis. Here, we identify TMEM41B, an endoplasmic reticulum-resident protein, as a critical regulator of bone homeostasis through its actions in bone marrow adipocytes (BMAs). Adipocyte-specific deletion of TMEM41B in mice (TMEM41B AKO) significantly increased bone mass, improved trabecular and cortical bone parameters, and enhanced mechanical strength, particularly in long bones.

2025-09-23 | PXD068718 |

Metridium senile

Project description:Metridium senile overview

| PRJNA256218 | ENA

The long noncoding RNA lnc-ob1 facilitates bone formation by upregulating Osterix in osteoblasts

Project description:Long noncoding RNAs (lncRNAs) have emerged as integral regulators of physiology and disease, but specific roles of lncRNAs in bone disease remain largely unknown. Here, we show that lnc-ob1 regulates osteoblast activity and bone formation in mice by upregulating the osteogenic transcription factor Osterix. Expression of lnc-ob1 is enriched in osteoblasts and upregulated during osteoblastogenesis. We demonstrate that osteoblast-specific knock-in of lnc-ob1 enhances bone formation and increases bone mass. Pharmacological overexpression of lnc-ob1 specifically in osteoblasts confers resistance to ovariectomy-induced osteoporosis in mice. In humans, expression of the homologue, lnc-OB1, decreases with age in osteoblasts of patients with osteoporosis. Mechanistically, lnc-ob1 upregulates the expression of Osterix in mouse and human osteoblasts, probably via inhibition of H3K27me3 methylation. Our data indicate that lnc-OB1 regulates bone formation and might be a drug target for the treatment of osteoporosis.

2019-03-28 | GSE112318 | GEO

The mechanosensitive adhesion G protein-coupled receptor GPR133/ADGRD1 enhances bone formation – a potential new target for osteoporosis treatment

Project description:Osteoporosis poses an increasing health and socioeconomic burden on aging societies. Current therapeutic options often present potentially severe side effects or lack long-term efficacy, underscoring the need for more effective treatments. Establishing novel drug targets requires an in-depth understanding of their physiological roles. Here, we describe the impact of the adhesion G protein-coupled receptor GPR133/ADGRD1 on osteoblast differentiation and function. Constitutive and osteoblast-specific knockouts of GPR133/ADGRD1 in mice result in reduced cortical bone mass and increased trabecularization in femurs and vertebrae—features characteristic of osteoporosis. Genome-wide association studies in humans link GPR133/ADGRD1 gene variants to differences in bone mineral density and body height. At the molecular level, GPR133/ADGRD1 influences osteoblast function and differentiation through a combined activation mechanism involving interaction with its endogenous ligand PTK7 and mechanical forces. In vitro analysis shows that osteoblast differentiation is driven by cAMP-dependent activation of the b-catenin signaling pathway. Activation of GPR133/ADGRD1 with the receptor-specific ligand AP503 promotes osteoblast function and differentiation both in vitro and in vivo, significantly alleviating osteoporosis in a mouse ovariectomy model. This renders GPR133/ADGRD1 a promising therapeutic target for osteoporosis and other diseases characterized by reduced bone mass.

2025-06-04 | GSE298885 | GEO

Metridium senile

Project description:Metridium senile Genome sequencing

| PRJNA212399 | ENA

The SIK2/SIK3 inhibitor GLPG3970 increases bone formation and trabecular bone mass in hypogonadal female mice and rats

Project description:Currently, there are no orally available bone anabolic therapies to treat osteoporosis. Intermittent parathyroid hormone injections stimulate bone formation through a signaling pathway that inhibits the actions of salt inducible kinase (SIK) isoforms 2 and 3. Therefore, direct small molecule SIK2/SIK3 inhibitors represent a promising treatment strategy to mimic PTH actions. Here we tested GLPG3970, a potent and selective SIK2/SIK3 inhibitor developed for clinical use in inflammatory diseases, in rodent models of post-menopausal osteoporosis. In bone cells, GLPG3970 reduces phosphorylation levels of SIK substrates and regulates gene expression patterns, as assessed by RNA-sequencing, in a PTH-like manner. GLPG3970 was administered to female mice and rats rendered hypogonadal via surgical oophorectomy (OVX) via twice daily oral gavage. In parallel, separate groups of rodents were treated with once daily subcutaneous PTH injections. Skeletal endpoints, serum bone turnover markers, micro-CT, histomorphometry, and mechanical testing, were assessed after study termination. In both OVX-operated mice and rats, GLPG3970 treatment increased markers of bone formation and cancellous bone mass, and increased rat vertebral body bone strength. These results provide strong justification for further development of orally available SIK2/SIK3 inhibitors to treat post-menopausal osteoporosis.

2025-09-01 | GSE285777 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data